Notably, the AKT inhibitor triciribine alone had a cytostatic effect on tumor cells but did not preferentially inhibit CD133+ tumor-initiating cells, whereas the PPARγ agonist rosiglitazone selectively targeted HCC TICs. This evidence concerns the gene AKT1 and neoplasm.